Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2534 • ACR Convergence 2024
Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
Juan Vargas¹, Ian Mantel², Jun Inamo³, Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao⁵, Susan Goodman⁶, Kevin Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri¹¹, Trent Woodruff¹², the Accelerating Medicines Partnership (AMP) RA/SLE Network¹³, Michael Holers¹⁴, Laura Donlin¹⁵ and Fan Zhang¹⁶, ¹The University of Colorado, Aurora, CO, ²WEILL CORNELL MEDICINE, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University of Queensland, Brisbane, Australia, ¹³AMP RA/SLE consortium, Aurora, CO, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of Colorado, Aurora, CO
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: 0037 • ACR Convergence 2024
Clonal Haematopoiesis of Indeterminate Potential (CHIP) Is Associated with Disease Activity in Rheumatoid Arthritis
Athena Chin¹, Sue Branford², Annabelle Small³, katie Lowe³, malcolm Smith⁴, Monika Kutyna⁵, Robert King², Susanna Proudman⁶, Devendra Hiwase⁷ and Mihir Wechalekar⁸, ¹Royal Adelaide Hospital, Tranmere, South Australia, Australia, ²SA Pathology, Adelaide, Australia, ³Flinders University, Adelaide, Australia, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵South Australian Health and Medical Research Institute, Adelaide, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Clonal haematopoiesis (CH) of indeterminate potential (CHIP) is defined as the detection of recurrent somatic mutations in genes that are known to drive haematological…
Abstract Number: 0054 • ACR Convergence 2024
Supernatants from Macrophages Stimulated with Citrullinated and MAA-Modified Fibrinogen Contain PDGF-BB and TGF-b and Upregulate Fibrotic Markers in Human Lung Fibroblasts
Nozima Aripova¹, Michael Duryee¹, Bryant England¹, Carlos Hunter¹, Lauren Klingemann¹, Nigina Aripova², Amy Nelson¹, Jill Poole¹, Dawn Katafiasz¹, Kristina Bailey¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²WUSTL, St. Louis, MO
Background/Purpose: Lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) have greater levels of malondialdehyde-acetaldehyde adducts (MAA) that co-localize with citrullinated (CIT) and…
Abstract Number: 0134 • ACR Convergence 2024
Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associated with an Increased Risk of Venous Thromboembolism: United Kingdom-population Based Study
James Galloway¹, Victoria Basey², Anna Barkaway³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: While the use of oral contraceptives in females with immune mediated inflammatory diseases such as rheumatoid arthritis (RA) is acknowledged as a risk factor…
Abstract Number: 0214 • ACR Convergence 2024
Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Justin Dunn¹, Scott Matson², Michael George³, Yangyuna Yang¹, Punyasha Roul⁴, Jorge Rojas⁵, grant Cannon⁶, Sauer brian⁷, Jeffrey Curtis⁸, Joshua Baker³, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Kansas, Kansas City, MO, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵Seattle VA, Mexico, Mexico, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The American College of Rheumatology (ACR) and American College of Chest Physicians (CHEST) recently released clinical practice guidelines for the treatment of RA-interstitial lung…
Abstract Number: 0358 • ACR Convergence 2024
Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors
Rosa Maria Morlà Novell¹, Beatriz Frade-Sosa², Lola Tobalina Maestre³, Meritxell Sallés Lizarzaburu⁴, Virginia Ruiz-Esquide², Maria López Lasanta⁵, Georgina Salvador Alarcón⁶, Noemí Busquets Pérez⁷, Marta Valls Roc⁸, Enrique Gonzalez Dávila⁹, Jose Alfredo Gomez-Puerta¹⁰ and Raimon Sanmartí Sala¹⁰, and ARCat study Group, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³Fundació Clinic per la Recerca clínica, Barcelona, Spain, ⁴Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, ⁵Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ⁶Hospital Mútua de Terrassa, Terrassa, Spain, ⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁸Hospital Universitari Josep Trueta, Girona, ⁹Universidad de La Laguna, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Fatigue is a frequent and annoying symptom in rheumatoid arthritis (RA) patients that is often not assessed at routine follow-up visits. Residual’ fatigue has…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0474 • ACR Convergence 2024
Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Joshua Hsieh¹, Avneet Kaur², Hemant Khandelia³, Teresa Jewell⁴, Aman Singh⁵, Lauren Barkley⁶, Ishan Bansal⁷, Simmi Oberoi⁸ and Namrata Singh⁹, ¹Lakeside High School, Seattle, WA, ²SUNY Upstate, Buffalo, NY, ³AIIMS, New Delhi, Delhi, India, ⁴University of Washington, Seattle, WA, ⁵Rajindra Hospital, Patiala, Punjab, India, ⁶Brandeis University, Boston, MA, ⁷Yale University, New Haven, CT, ⁸Rajindra Hospital, New Delhi, India, ⁹University of Washington, Bellevue, WA
Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…
Abstract Number: 0492 • ACR Convergence 2024
A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Michael Dreyfuss¹, Yonatan Jenudi², Dan Riesel³, Or Ramni³, Daniel Underberger⁴, Benjamin Getz⁵, Shlomit Steinberg-Koch³, Douglas White⁶ and Elena Myasoedova⁷, ¹Predicta Med, Ramat Gan, Israel, ²[email protected], Ramat Gan, Israel, ³Predicta Med Analytics Ltd., Ramat Gan, Israel, ⁴Predicta Med Analytics Ltd., Bridgeport, CT, ⁵CTO, Ramat Gan, Israel, ⁶Gundersen Health System, Onalaska, WI, ⁷Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis often experience clinically significant delays in diagnosis (Sørensen et al., 2015; Raza et al., 2011). RA can present similarly to…
Abstract Number: 0508 • ACR Convergence 2024
Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data
Xenofon Baraliakos¹, Cristofer Salvati², Elena Bachinskaya², Samriddhi Sinha² and Klaus Krüger³, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²Medical Affairs, Sandoz Hexal AG, Holzkirchen, Germany, Holzkirchen, Germany, ³Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: GP2015 is an etanercept biosimilar indicated for the treatment of rheumatoid arthritis (RA).1 The objective of this abstract is to describe the baseline characteristics…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 0796 • ACR Convergence 2024
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Carlos Raul Ramirez Medina¹, Mark Lunt², David Jenkins², William Dixon², Niels Peek³ and Meghna Jani², ¹The University of Manchester, Warrington, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³THIS Institute , University of Cambridge, Cambridge, United Kingdom
Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe's highest opioid-related hospital admissions.…
Abstract Number: 0883 • ACR Convergence 2024
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Jorge Monserrat¹, Cristina Bohorquez², Ana Maria Gómez³, Elena Rabadán Rubio⁴, Raquel Sánchez³, Atusa Movasat⁵, Lucia Ruiz⁴, Fernando Albarran Hernandez⁶, Miguel Ángel Ortega¹, Ana Perez⁶ and Melchor Alvarez-Mon⁷, ¹Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ³Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, ⁴Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁶Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁷Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…

« Previous Page
1
…
6
7
8
9
10
…
188
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].